Protocol
10-226
Full Title
A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Purpose
Everolimus and bevacizumab are two drugs already approved for treating advanced renal cell carcinoma, a serious form of kidney cancer. In this study, researchers are evaluating the safety and effectiveness of using both drugs together in patients with advanced non-clear cell renal cell cancer. The hope is that both drugs together may be more effective than either drug alone.
Everolimus is an oral drug that inhibits a molecule called mTOR, which helps cancer cells grow. Bevacizumab inhibits the formation of blood vessels that tumors need to grow and spread. It is given intravenously (by vein).
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have advanced non-clear cell renal cell cancer.
- Patients may not have previously received sunitinib, sorafenib, bevacizumab, sirolimus, temsirolimus, everolimus, or deforolimus.
- At least 4 weeks must have passed since any major surgery or radiation therapy and entry into the study.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Ana M. Molina at 646-422-4313.
Disease(s)
Kidney Cancer
Locations
ClinicalTrials.gov
Related Diseases
